Foff Erin Pennock 4

What Happened

• Erin Pennock Foff, Chief Medical Officer of MapLight Therapeutics (MPLT), sold a total of 50,280 shares in multiple open‑market transactions executed May 4–6, 2026. The combined proceeds reported were $1,427,594.
• Individual reported lots: 9,180 @ $27.50 ($252,450); 5,460 @ $28.37 ($154,900); 312 @ $29.56 ($9,223); 700 @ $30.08 ($21,056); 9,645 @ $28.12 ($271,217); 931 @ $29.00 ($26,999); 8,152 @ $28.04 ($228,582); and 15,900 @ $29.13 ($463,167). These are sales (routine disposition of shares), not purchases.

Key Details

• Transaction dates: May 4–6, 2026. Form filed on May 6, 2026 reporting the period May 4, 2026.
• Total shares sold: 50,280. Total proceeds: $1,427,594.
• 10b5‑1 plan: The filing notes at least one transaction was made pursuant to a Rule 10b5‑1 trading plan adopted by the reporting person on December 29, 2025 (see footnote F1).
• Price reporting: Many line items use weighted average prices; the filing includes footnotes showing the ranges of individual trade prices (see F2–F9 for ranges roughly spanning ~$26.84 to ~$30.55).
• Shares owned after the transactions: Not specified in the excerpt provided — check the full Form 4 for post‑trade holdings.
• Timeliness: Filing date is May 6, 2026; no late‑filing flag was provided in the data you supplied.

Context

• Sales by executives are often routine (e.g., part of pre‑arranged plans or diversification) and do not, by themselves, indicate a change in company outlook. The presence of a Rule 10b5‑1 plan means at least some trades were pre‑scheduled.
• For full details (exact per‑trade timestamps, exact per‑trade prices within the reported weighted averages, and current holdings), consult the official Form 4 (Accession No. 0002021233-26-000008) on the SEC EDGAR site.